[Intra-arterial chemotherapy in urological cancer].
We herein describe the present status of intra-arterial chemotherapy for patients with renal cell carcinoma and bladder cancer, and discuss the prospect of intra-arterial chemotherapy in these urological diseases. The combination of immunotherapy and intra-arterial chemoembolization with microcapsules may prolong the survival of patents with unresectable tumors. However, the role of intra-arterial chemotherapy in renal cell carcinoma is limited. For bladder cancer, several modifications to increase the effect of intra-arterial chemotherapy have been documented. The combination of intra-arterial chemotherapy and radiotherapy resulted in a complete response rate of 84-91%, supporting the possibility of bladder preservation for patients with invasive bladder cancer. To establish the effectiveness of intra-arterial chemotherapy, large scaled prospective randomized studies are necessary.
Mitsumori
Kenji
K
Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan.
Sato
Kazunari
K
Kato
Teturou
T
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002214:Capsules; D002292:Carcinoma, Renal Cell / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000592:standards / Q000639:trends; D007680:Kidney Neoplasms / Q000628:therapy; D016685:Mitomycin / Q000008:administration & dosage*; D001749:Urinary Bladder Neoplasms / Q000628:therapy; D014571:Urologic Neoplasms / Q000628:therapy*
D000903:Antibiotics, Antineoplastic; D002214:Capsules; D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin